Status:
RECRUITING
Comparision of Hydrodilatation Results at Different Volumes in Adhesive Capsulitis by Phases.
Lead Sponsor:
Javier Muñoz Paz
Collaborating Sponsors:
Universidad de Córdoba
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC)
Conditions:
Capsulitis of Shoulder
Hydrodilatation
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
Adhesive capsulitis (AC) causes a global limitation of active and passive range of motion (ROM) in the shoulder, with or without pain, and no other radiographic findings. The natural process is self-l...
Eligibility Criteria
Inclusion
- Ages between 30 and 70 years.
- Limited ROM, both active and passive, in two planes.
- Shoulder pain lasting more than 3 months.
Exclusion
- Lidocaine + trial with improved ROM.
- Conditions that preclude treatment (active cancer, tissue infection, oral anticoagulant use, cardiac arrhythmias, etc.)
- Previously receiving HD treatment in less than 1 year.
- Stage 0 or 3 AC.
- Non-adherence to the PT program, with attendance failures exceeding 20%.
- Presence of conditions that can cause similar symptoms, such as acromioclavicular osteoarthritis, labral injury, massive rotator cuff tear, or rheumatic diseases.
- Intra-articular corticosteroid injection in less than 2 months.
- Technique failure.
Key Trial Info
Start Date :
February 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06939530
Start Date
February 2 2025
End Date
January 1 2026
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Reina Sofia
Córdoba, Spain, 14004